Premium
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone
Author(s) -
Derosa G.,
Fogari E.,
D'Angelo A.,
Cicero A. F. G.,
Salvadeo S. A. T.,
Ragonesi P. D.,
Ferrari I.,
Gravina A.,
Fassi R.,
Fogari R.
Publication year - 2007
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2007.00820.x
Subject(s) - telmisartan , irbesartan , medicine , endocrinology , rosiglitazone , metabolic syndrome , adiponectin , type 2 diabetes , blood pressure , resistin , body mass index , diabetes mellitus , insulin resistance
Summary Background and objective: Angiotensin II receptor blockers represent a class of effective and well‐tolerated orally active antihypertensive drugs in the general hypertensive population and in diabetic patients. The aim of our study was to investigate the metabolic effects of telmisartan and irbesartan in diabetic subjects treated with rosiglitazone. Methods: We evaluated 188 type 2 diabetic patients with metabolic syndrome. All patients took a fixed dose of 4 mg rosiglitazone/day. We administered 40 mg telmisartan/day or 150 mg irbesartan/day and evaluated their body mass index, glycosylated haemoglobin (HbA 1c ), fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment‐index (Homa‐IR), total cholesterol (TC), low density lipoprotein‐cholesterol (LDL‐C), high density lipoprotein‐cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, adiponectin and resistin during 12 months of this treatment. Results and discussion: In addition to a comparable antihypertensive effect for telmisartan and irbesartan after 6 and 12 months, both treatments were associated with a significant reduction in TC and LDL‐C plasma levels compared with baseline. After 6 months of treatment, only the telmisartan group experienced a significant improvement in (HbA 1c ), FPG, Homa‐IR, adiponectin and resistin compared with the baseline values, whereas both drug regimens were associated with a significant improvement in these parameters after 12 months. However, the improvements observed in the telmisartan group were significantly larger than that noted in the irbesartan group after 12 months of treatment. FPI significantly decreased only after 12 months of treatment in both groups, but again, the reduction was significantly larger in the telmisartan‐treated subjects. Conclusions: Telmisartan seemed to improve glycaemic and lipid control and metabolic parameters of the metabolic syndrome better than irbesartan. These differences could be relevant in the choice of therapy for this condition and diabetes.